Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 29/03/19 at 11:24am

A Japanese journalist was ordered to pay ¥3.3 million to an anti-vaccine researcher, this week, after a court found her guilty of libel. The case is being taken as a major setback for those fighting misinformation surrounding vaccines.

Meanwhile the Department of Veteran Affairs (VA) said they would make Janssen’s ketamine-based treatment for depression, esketamine, available to veterans in the United States. In other news, Novartis said their new MS drug would cost $88,000 a year while Gilead were accused of ripping of US taxpayers after campaigners condemned the firm for capitalising on patents for PrEP drugs owned by the US government.

Our ‘Patient Experience’ feature also made it into the top ten this week as we heard from Dan Jeffries who told Pharmafocus of his experiences living with two rare diseases. Check out this week’s ten most popular stories on!

10. Gilead accused of ripping off US taxpayers

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in sales from preventative HIV drug Truvada, despite the fact it was developed  by the US government.

9. Sanofi and Lexicon's Zynquista denied type 1 diabetes approval by FDA complete response letter

Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type 1 diabetes in combination with insulin after the FDA responded to the pair’s regulatory application with a complete response letter (CRL).

8. Patient Experience: Living with two rare diseases

Dan Jeffries was diagnosed with the ultra-rare condition Wyburn-Mason syndrome at a young age, leaving him blind in one eye. But this occurrence, at a prevalence of one in 70 million, was compounded later in life when he found he was living with not one, but two rare conditions, complicating treatment and leading to some very close calls

7. NICE recommend Takeda's lymphoma treatment Adcetris

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma (CTCL).

6. Advertising Standards Authority tells therapists to stop marketing 'autism cure'

The Advertising Standards Authority (ASA) has told British therapists to stop marketing a sham ‘cure’ for autism.

5. Department of Veteran Affairs to offer Janssen's esketamine to veterans with depression

The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is set to make Janssen’s Spravato (esketamine) available to veterans with depression.

4. Japanese court orders public health campaigner to pay ¥3.3 million to anti-vaccine researcher

Dr Riko Muranaka, a doctor and journalist who has campaigned against misinformation surrounding the HPV vaccine, has been ordered to pay ¥3.3 million ($30,000) in damages and legal fees to a controversial doctor who claimed the HPV vaccine was linked to neurological symptoms and brain damage.

3. Measles outbreak spurs New York County to ban all unvaccinated children from public spaces

Rockland County, New York State, is taking serious measures to combat its biggest measles outbreak in decades, making the decision to ban all unvaccinated children from all public spaces.

2. Novartis' new MS drug to cost $88,000 a year

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will cost $88,000 a year.

1. Novo Nordisk's oral semgalutide outclasses Januvia with new data in type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the drug achieved “superior reductions” in blood sugar, and body weight compared to MSD’s Januvia (sitagliptin 100 mg).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches